胸腺肽联合阿德福韦酯对原发性肝癌患者AFP、瘤体改善及近期疗效的影响  

Effects of Thymosin Combined with Adefovir Dipivoxil on AFP,Tumor Improvement and Short-term Efficacy of Primary Hepatocellular Carcinoma

作　　者：王谢[1] 刘俊华[1] 李晓华[1] WANG Xie;LIU Junhua;LI Xiaohua(Zhengzhou Sixth People's Hospital,Zhengzhou,450000)

机构地区：[1]河南省郑州市第六人民医院,450000

出　　处：《实用癌症杂志》2020年第6期971-974,共4页The Practical Journal of Cancer

基　　金：洛阳市科技计划医疗卫生项目(编号:1720001A-6)。

摘　　要：目的探究胸腺肽联合阿德福韦酯对原发性肝癌患者血清甲胎蛋白(AFP)、瘤体改善及近期疗效的影响。方法将70例原发性肝癌患者随机分成2组,每组35例。一组为对照组,采用常规保肝治疗;另一组为观察组,在对照组治疗的基础上,联合使用胸腺肽和阿德福韦酯进行治疗。观察比较2组患者的瘤体改善和近期疗效、治疗后AFP复常率以及生活质量改善情况。结果观察组患者的疾病控制率、总有效率分别为80.00%、48.57%,对照组患者的疾病控制率、总有效率分别为54.29%、28.57%,2组数据存在明显差异(P<0.05),具有统计学意义。观察组患者治疗后12周、24周、48周AFP复常率分别为60.00%、71.43%、88.57%,对照组患者治疗后12周、24周、48周AFP复常率分别为34.29%、45.86%、57.14%,2组数据存在明显差异(P<0.05),具有统计学意义。观察组患者的生活质量改善率为80.00%,明显高于对照组患者的改善率51.43%,2组数据存在明显差异(P<0.05),具有统计学意义。结论胸腺肽联合阿德福韦酯辅助治疗原发性肝癌,能够有效促进患者的AFP恢复正常,改善瘤体,提高近期治疗效果和生活质量。Objective To explore the effect of thymosin combined with adefovir dipivoxil on serum alpha-fetoprotein(AFP),tumor improvement and short-term efficacy of primary hepatocellular carcinoma(PHC).Methods 70 patients with primary hepatocellular carcinoma were selected and randomly divided into 2 groups,35 patients in each group,one group as the control group,using routine hepatoprotective therapy.The other group was the observation group,which was treated with thymosin and adefovir dipivoxil on the basis of the control group.To observe and compare the improvement of tumors and short-term curative effect,the normalization rate of AFP after treatment,and the improvement of quality of life between the 2 groups.Results The disease control rate and total effective rate in the observation group were 80%and 48.57%respectively,while those of the control group were 54.29%and 28.57%respectively.There were significant differences between the 2 groups(P<0.05).The recovery rates of AFP in the observation group were 60%,71.43%,88.57%at 12,24 and 48 weeks after treatment,and 34.29%,45.86%and 57.14%at 12,24 and 48 weeks after treatment in the control group,respectively.There was significant difference between the 2 groups(P<0.05).The improvement rate of quality of life in the observation group was 80%,which was significantly higher than that of the control group(51.43%).There was a significant difference between the 2 groups(P<0.05).Conclusion Thymosin combined with adefovir dipivoxil in the treatment of primary hepatocellular carcinoma can effectively promote the recovery of AFP,improve the tumors,and improve the short-term therapeutic effect and quality of life.

关 键 词：胸腺肽 阿德福韦酯 原发性肝癌 血清甲胎蛋白 瘤体 疗效 

分 类 号：R735.7[医药卫生—肿瘤]